Reclast (Zoledronic Acid) Side Effects: Incidence Rates Across Trials

Zoledronic acid, marketed as Reclast, is a nitrogen-containing bisphosphonate administered as a single 5 mg intravenous infusion typically given once yearly to treat postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget's disease of bone. Zometa, which contains the same molecule at a different strength, is administered at 4 mg every three to four weeks for cancer-related bone disease in a distinct clinical setting with its own safety considerations. The following information focuses on zoledronic acid use for osteoporosis unless otherwise noted.

Direct answer: The most common adverse effect of Reclast is a transient flu-like acute phase reaction after the first infusion, affecting a substantial minority of patients and largely resolving within a few days. Serious but far less frequent risks include atrial fibrillation, kidney function changes, osteonecrosis of the jaw, and atypical femoral fracture, the last of which becomes more likely the longer a patient stays on bisphosphonate therapy. These serious risks are individually uncommon at osteoporosis-dose exposure, but they are not zero, and the atypical fracture risk in particular is duration-dependent rather than fixed.

A note on the numbers in this article

The landmark trial for Reclast's safety profile is the HORIZON Pivotal Fracture Trial (HORIZON-PFT), a large randomized, placebo-controlled study of postmenopausal women published by Black and colleagues in the New England Journal of Medicine in 2007. Specific percentage figures for adverse events in this article are drawn from that trial and from the FDA-approved prescribing information as commonly cited in the osteoporosis literature. Because this draft is undergoing evidence verification, editors and clinicians should confirm exact percentages against the primary HORIZON-PFT publication and the current FDA label before using them for patient counseling or clinical decisions. Where a number could not be tied to a specific, checkable source in this draft, it has been described qualitatively (common, uncommon, rare) rather than presented as a precise figure.

What zoledronic acid does and why the side effects cluster the way they do

Zoledronic acid binds to bone mineral at sites of active remodeling and inhibits farnesyl pyrophosphate synthase inside osteoclasts, shutting down bone resorption. That mechanism explains most of the adverse event pattern:

• Nitrogen-containing bisphosphonates activate gamma-delta T cells on first exposure, producing the acute phase (flu-like) reaction.
• The drug is cleared by the kidney, and infusion rate and hydration status affect renal exposure.
• Long-term, potent suppression of bone turnover is mechanistically linked to two rare but serious outcomes: osteonecrosis of the jaw and atypical femoral fracture, both associated with impaired bone repair rather than an acute toxic effect.

Acute phase reaction: the most common adverse event

The acute phase reaction consists of fever, muscle aches, joint pain, headache, and fatigue, usually starting one to three days after infusion and resolving within about three days. In the HORIZON-PFT population, roughly a third of patients reported at least one component of this reaction after their first infusion, with pyrexia and myalgia among the most frequently reported individual symptoms. The reaction becomes markedly less common with each subsequent annual dose, consistent with the immune cells that drive it becoming less reactive after repeated exposure.

Two measures reduce the severity of this reaction and appear in the FDA prescribing information: taking acetaminophen around the time of infusion and continuing it for about 24 hours, and drinking roughly 500 mL of fluid in the two hours before infusion. Neither eliminates the reaction, and patients should be told to expect it rather than assume it means something has gone wrong.

Kidney effects

Zoledronic acid is renally cleared, and the FDA label requires the infusion to run over at least 15 minutes and specifies a baseline creatinine check, because faster infusion concentrates drug delivery to the kidney. HORIZON-PFT recorded transient serum creatinine increases in a small but meaningfully higher proportion of zoledronic acid patients than placebo patients, and most of these resolved. The FDA label for Reclast states the drug is contraindicated when creatinine clearance is below 35 mL/min.

Patients with moderate chronic kidney disease occupy a gray zone that requires individualized judgment: adequate pre-infusion hydration, avoidance of concurrent nephrotoxic drugs such as NSAIDs around the infusion window, and closer creatinine monitoring are reasonable precautions, but a firm cutoff below the label's contraindication threshold is not established by current guidance.

Atrial fibrillation: a signal that regulators found inconclusive

HORIZON-PFT recorded a higher rate of serious atrial fibrillation (events requiring hospitalization or judged life-threatening) in the zoledronic acid group than the placebo group. This finding prompted a formal FDA review. Regulators who examined the available data, including HORIZON-PFT and other bisphosphonate trials, concluded that a causal relationship between bisphosphonate use and atrial fibrillation had not been established. This is a case where a real trial signal did not survive regulatory scrutiny as a confirmed causal effect. Clinicians reasonably continue to document baseline cardiac history before infusion, but patients should not be told that Reclast is a confirmed cause of atrial fibrillation.

Osteonecrosis of the jaw

Osteonecrosis of the jaw (ONJ) is the adverse event patients most often ask about, largely driven by oncology case reports involving the much higher cumulative dosing used for cancer-related bone disease. At osteoporosis dosing, ONJ is understood to be rare, on the order of a small fraction of one percent per patient-year, though exact incidence estimates vary across studies and populations and should be treated as approximate. At oncologic dosing (4 mg every three to four weeks), reported ONJ rates are substantially higher, reflecting the much larger cumulative drug exposure. A recent report on skeletal-related event prevention in multiple myeloma illustrates that oncologic bisphosphonate dosing is aimed at a different clinical goal, reducing fractures and bone complications from malignancy, than osteoporosis dosing, and the two contexts should not be compared on the same risk scale (skeletal-related event prevention in multiple myeloma, 2026).

Known risk factors for ONJ include invasive dental procedures performed while on bisphosphonate therapy, periodontal disease, poor oral hygiene, concurrent corticosteroid use, and smoking. Standard practice is to complete elective invasive dental work before starting therapy when it can be delayed without harm. Evidence on whether a temporary pause in bisphosphonate therapy ("drug holiday") before dental surgery reduces ONJ risk at osteoporosis doses is limited and mixed; individualized risk stratification, not a blanket holiday, is the more defensible approach given current uncertainty.

Atypical femoral fracture: the risk that grows with duration

Atypical femoral fracture (AFF) is the clearest example of a paradox in bisphosphonate therapy: a drug given to prevent fractures can, after years of use, contribute to an unusual fracture pattern. AFF occurs in the subtrochanteric or femoral shaft region, with little or no trauma, often preceded by weeks to months of thigh or groin pain, and with a transverse or short oblique fracture line rather than the spiral pattern typical of ordinary femur fractures.

The epidemiological pattern reported in the literature is duration-dependent: AFF is uncommon in the first few years of bisphosphonate use and becomes more frequent, though still uncommon in absolute terms, after roughly eight or more years of continuous therapy. A recent case report describes bilateral atypical femoral fractures in a patient with long-term bisphosphonate use following breast cancer surgery, which is consistent with the recognized pattern that AFF can present bilaterally and that a fracture on one side should prompt imaging of the other femur (bilateral atypical femoral fracture case report, 2026). For general background on femoral and hip fracture patterns and treatment context, a recent review of hip fractures is a useful reference (Hip Fractures: A Review, 2026).

Prodromal thigh or groin pain is reported in a majority of patients before a complete AFF. Any patient on long-term zoledronic acid who develops new thigh pain should have bilateral femur imaging promptly rather than waiting for the pain to resolve on its own.

Hypocalcemia

Reclast is contraindicated in patients with pre-existing hypocalcemia, and the drug's potent suppression of bone resorption can transiently lower serum calcium after infusion. HORIZON-PFT recorded a modestly higher rate of hypocalcemia in the treatment group than placebo during the first year, and severe symptomatic hypocalcemia is uncommon at osteoporosis dosing but has been reported in patients with unrecognized vitamin D deficiency, hypoparathyroidism, or malabsorption. Correcting vitamin D and ensuring adequate calcium intake before infusion, per the FDA label and consistent with endocrine guideline practice, is standard preparation.

Musculoskeletal pain, apart from the acute phase reaction

The FDA added a class-wide bisphosphonate label warning for severe, incapacitating bone, joint, and muscle pain that is distinct from the acute phase reaction and can appear months to years into therapy rather than only after the first dose. This pattern has been reported in post-marketing surveillance, and in some patients the pain has resolved on stopping the drug and recurred on restarting it, which supports a drug-related mechanism rather than coincidence.

Ocular inflammation

Uveitis, scleritis, episcleritis, and orbital inflammation are uncommon but recognized reactions to intravenous bisphosphonates, typically appearing within the first one to two days after infusion. Systematic incidence data are limited because eye examinations were not routinely performed in the major osteoporosis trials. Any new eye pain, redness, or vision change after a Reclast infusion warrants prompt ophthalmology evaluation rather than waiting to see if it resolves.

What the evidence establishes, what is plausible but unproven, and what is not established

Established: the acute phase reaction is common after the first dose and fades with subsequent doses; Reclast is renally cleared and contraindicated below a creatinine clearance threshold specified in the label; ONJ and AFF are real but uncommon risks at osteoporosis dosing that both scale with cumulative bisphosphonate exposure; the atrial fibrillation signal in HORIZON-PFT did not hold up as a confirmed causal relationship after FDA review.

Plausible but unproven: that a drug holiday after dental extraction meaningfully lowers ONJ risk at osteoporosis dosing; that precise numeric ONJ and AFF incidence figures generalize cleanly across different patient populations and dosing durations, given how much these estimates vary by study design and population.

Not established: a confirmed causal link between zoledronic acid and atrial fibrillation; a universally agreed optimal duration of therapy, which the FDA label itself leaves undetermined; individualized dosing or discontinuation timing for any specific reader, which requires a clinician who knows the patient's fracture risk, renal function, and dental history.

Drug holidays and long-term management

Guidance from bone specialty societies has suggested considering a pause in IV zoledronic acid after roughly three years in patients at lower fracture risk (higher hip bone density, no prior vertebral fracture), and continuing longer in higher-risk patients before reassessment. The FDA prescribing information itself states that the optimal duration of use has not been determined. This is a judgment call made jointly by patient and prescriber based on fracture risk, not a fixed rule, and reflects guideline-level reasoning rather than a single definitive trial answer.

Original HealthRX.com framework: pre-infusion risk screen and decision points

This is a structured way to think through what actually changes the decision to proceed with, delay, or modify a Reclast infusion. It does not replace individualized clinical judgment, and it should be applied by the treating clinician, not used by a patient to self-triage.

1. Renal function check. Get a serum creatinine and calculate eGFR within about 10 days of the planned infusion.

• If eGFR is below 35 mL/min/1.73m², do not infuse; this is a labeled contraindication.
• If eGFR is 35 to 44, proceed with caution, ensure pre-infusion hydration, and avoid NSAIDs for 48 hours around the infusion.
• Exception: if the patient has acute, reversible volume depletion (illness, vomiting), correct hydration first and recheck creatinine before deciding, rather than treating a transient number as a permanent contraindication.

2. Mineral status check. Check 25-OH vitamin D and confirm adequate calcium intake.

• If vitamin D is deficient, correct it before infusing rather than after; infusing into a deficient patient raises hypocalcemia risk.
• Ask specifically about prior thyroid or parathyroid surgery and malabsorptive conditions, which raise hypocalcemia risk beyond the average patient.

3. Dental status check. Ask directly whether any extraction, implant, or other invasive dental work is planned in the next several months.

• If yes, delay the infusion until the dental work and healing are complete, when that delay does not create unacceptable fracture risk in the interim.
• This is a tradeoff, not a free choice: delaying osteoporosis treatment also carries a fracture-risk cost, so the decision should weigh the patient's baseline fracture risk against the dental timeline.

4. Cumulative duration and fracture-pattern check. For any patient with more than about five years of cumulative bisphosphonate exposure across any agent, ask specifically about new thigh or groin pain at every visit.

• If present, order bilateral femur imaging before proceeding with another infusion, because AFF can be bilateral and unilateral symptoms can precede fracture on the other side.
• This is also the point to revisit whether a drug holiday is appropriate, based on the patient's current fracture risk rather than defaulting to indefinite continuation.

Next step if any domain fails: hold the infusion, address the failing domain, and reassess rather than proceeding on schedule by default. The infusion date is not more urgent than correcting a modifiable risk factor first.

When to seek urgent care rather than waiting

New chest pain, palpitations, or fainting after infusion; new eye pain or vision change; jaw pain, swelling, or exposed bone; and new thigh or groin pain in a long-term user are all reasons to contact a clinician promptly rather than waiting for a scheduled follow-up. Fever and body aches in the first few days after a first infusion are expected and generally do not require urgent evaluation unless accompanied by these other warning signs or unless the fever is high or persistent.